National Alopecia Areata Foundation

NAAF’s Inaugural Walk For Alopecia Scheduled for September 30, 2023

Retrieved on: 
Wednesday, August 30, 2023

San Rafael, CA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- For anyone living with or touched by alopecia areata, you do not have to walk alone!

Key Points: 
  • San Rafael, CA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- For anyone living with or touched by alopecia areata, you do not have to walk alone!
  • The National Alopecia Areata Foundation is holding its first ever Walk For Alopecia at Lake Merced in San Francisco on Saturday, September 30.
  • The Walk For Alopecia will be a wonderful gathering of support and camaraderie for anyone touched by alopecia areata.
  • Registration is free and anyone that raises $200 will receive the inaugural Walk For Alopecia T-shirt.

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

Retrieved on: 
Friday, June 23, 2023

It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.

Key Points: 
  • It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.
  • “LITFULO is an important treatment advancement for alopecia areata, an autoimmune disease that previously had no FDA-approved options for adolescents and limited options available for adults,” said Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, Pfizer.
  • “With today’s approval, adolescents and adults who struggle with substantial hair loss have an opportunity to achieve significant scalp hair regrowth.”
    The FDA approval was based on results of clinical trials in alopecia areata.
  • “We believe the approval of LITFULO is a significant advancement for the treatment of alopecia areata, particularly for teens.

Global Alopecia Treatment Market 2022 to 2027: Featuring Sun Pharmaceutical Industries, GlaxoSmithKline, Cipla and HCell Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023

The "Global Alopecia Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Alopecia Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global alopecia treatment market is projected to grow at a CAGR of 8.44% to reach US$6,243.741 million by 2027, from US$3,539.835 million in 2020.
  • Alopecia areata patchy, alopecia areata totalis, and alopecia areata Universalis are the most common types of alopecia areata.
  • The Alopecia area has three types, including alopecia areata patchy, alopecia areata totalis, and alopecia areata Universalis, among others.

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Retrieved on: 
Tuesday, June 14, 2022

"I am so happy that adults with severe alopecia areata can now take OLUMIANT, a once-daily pill.

Key Points: 
  • "I am so happy that adults with severe alopecia areata can now take OLUMIANT, a once-daily pill.
  • "There is a significant unmet medical need for people with alopecia areata given there has never been an FDA-approved systemic medicine.
  • OLUMIANT's approval is a historic moment, and we're delighted about what it can mean for adults with severe alopecia areata."
  • In these double-blind, placebo-controlled Phase 3 trials, 1,200 patients with severe AA were randomized to receive once-daily OLUMIANT 2-mg, OLUMIANT 4-mg or placebo.

Global Laser Hair Loss Treatment Market Report 2021: Initiatives Focused on Increasing Awareness of Alopecia Areata to Spur the Market - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 22, 2021

The "Laser Hair Loss Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Laser Hair Loss Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Demand for non-invasive and pain-less treatment options is also fuelling demand for treatments like laser hair loss treatment.
  • Consumers have also been showing much confidence in some of the technologically advanced laser options developed recently for laser hair loss treatment.
  • Increasing proliferation of alternatives to laser hair loss treatment however, hold the potential to hinder anticipated growth for the market.

Immunitas Therapeutics Names Amanda Wagner as CEO

Retrieved on: 
Tuesday, November 16, 2021

WALTHAM, Mass., Nov. 16, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, has named Amanda Wagner, MBA, to lead the company as the new chief executive officer.

Key Points: 
  • WALTHAM, Mass., Nov. 16, 2021 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, has named Amanda Wagner, MBA, to lead the company as the new chief executive officer.
  • Wagner is a founding member of Immunitas and has made significant contributions to the company's business strategy and corporate development.
  • "I am honored to assume the role of CEO at Immunitas, and excited for the future of the company," said Wagner.
  • "With Amanda as CEO and Thomas Tan as chief scientific officer, we have a great leadership team in place to advance the science and develop novel therapeutics."

William Gaunitz, FWTS, Releases New Educational Video for September's Alopecia Areata Awareness Month

Retrieved on: 
Wednesday, September 1, 2021

Incredibly underwhelming yet so many are fearful of sitting at a trichology or dermatology office and being told 'you have alopecia.'

Key Points: 
  • Incredibly underwhelming yet so many are fearful of sitting at a trichology or dermatology office and being told 'you have alopecia.'
  • September is Alopecia Areata Awareness Month.
  • With Alopecia Areata your body is disrupting the growth cycle of the individual hair follicles in the predisposed area and typically manifests itself anywhere from the neck up.
  • Several celebrities including Viola Davis, Tyra Banks, Christopher Reeve, and Neve Campbell, indulged publicly regarding their battles with Alopecia Areata.

Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month

Retrieved on: 
Tuesday, August 31, 2021

In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this important autoimmune disease.

Key Points: 
  • In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this important autoimmune disease.
  • The effort will unite U.S. cities in observation of Alopecia Areata Awareness Month, which is recognized annually during September.
  • Thank you also to all the landmarks coast to coast for recognizing the importance of Alopecia Areata Awareness Month by lighting it up blue for alopecia areata.
  • The Light It Up Blue 4 Alopecia Areata campaign is made possible by Concert Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005236/en/

Nutrafol Pledges to Open the Dialogue in Support of Hair Loss Awareness Month

Retrieved on: 
Wednesday, August 11, 2021

Hair loss can have a strong impact on mental well-being, confidence and self-image among both men and women.

Key Points: 
  • Hair loss can have a strong impact on mental well-being, confidence and self-image among both men and women.
  • In support of Hair Loss Awareness Month, Nutrafol will donate a portion of total revenue for the month of August to the National Alopecia Areata Foundation.
  • Nutrafol's contribution will directly benefit the National Alopecia Areata Foundation (NAAF) Youth Mentor Program which helps young children with alopecia cope with the stress of hair loss in a meaningful way.
  • According to the American Hair Loss Association ( americanhairloss.org ), 40% of American hair loss sufferers are women and 85% of men will have significant hair thinning by the age of 50.

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Retrieved on: 
Tuesday, November 3, 2020

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.
  • Based on the results from our Phase 2 program, we believe CTP-543 has the potential to offer patients a best-in-class treatment for moderate to severe alopecia areata, said James V. Cassella, Ph.D., Chief Development Officer, Concert Pharmaceuticals.
  • The end-of-phase 2 meeting with the FDA was held following positive results from a dose-ranging Phase 2 trial of CTP-543 in patients with moderate to severe alopecia areata.
  • There are millions of people around the world affected by and living with alopecia areata, said Andy Bryant, Acting Chief Executive Officer of the National Alopecia Areata Foundation.